Chinese utility weights for the EORTC cancer-specific utility instrument QLU-C10D
- PMID: 39269580
- DOI: 10.1007/s11136-024-03776-z
Chinese utility weights for the EORTC cancer-specific utility instrument QLU-C10D
Abstract
Objective: The aim of this study is to provide Chinese utility weights for the European Organization for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions (EORTC QLU-C10D) which is a preference-based cancer-specific utility instrument derived from the EORTC QLQ-C30.
Methods: We conducted an online survey of the general population in China, with quota sampling for age and gender. Each respondent was asked to complete a discrete choice experimental survey consisting of 16 randomly selected choice sets. The conditional logit model and mixed logit model were used to analyze respondents' preferences, and the goodness of fit of the model was tested.
Results: A total of 2003 respondents were included in the analysis. Utility decrements within dimensions were typically monotonic. Monotonic inconsistency issues in the Fatigue, Sleep, and Nausea dimensions were normalized by monotonicity correction. Physical functioning, Pain, and Role functioning were associated with the greatest utility weights, with the smallest decrements being in Bowel problems and Emotional functioning. The utility value for the worst health state was 0.083, i.e. slightly higher than being dead.
Conclusions: This study provides the first China-specific set of value for the QLU-C10D based on societal preferences of the Chinese adult general population. The value set can be used as a cancer-specific scoring system for economic evaluations of new oncology therapies and technologies in China.
Keywords: Cancer; China; Discrete choice experiment; Health state valuation; QLU-C10D.
Plain language summary
1. This study provides the first China-specific set of value for the QLU-C10D based on societal preferences of the Chinese adult general population. 2. The value set can be used as a cancer-specific scoring system for economic evaluations of new oncology therapies and technologies in China.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
Declarations. Conflict of interest: Madeleine King is the founding chair of the MAUCa Consortium. Richard Norman, Georg Kemmler and Nan Luo are members of MAUCa Consortium. Georg Kemmler and Madeleine T. King are members of EORTC QOL Group. As instrument developers, we are prone to bias towards our MAUI. All authors have no conflict of interest with each other. Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of Harbin Medical University (project identification code: HMUIRB2023005). Consent to participate: Informed consent was obtained from all individual participants included in the study.
Similar articles
-
Japanese value set for the EORTC QLU-C10D: A multi-attribute utility instrument based on the EORTC QLQ-C30 cancer-specific quality-of-life questionnaire.Qual Life Res. 2024 Jul;33(7):1865-1879. doi: 10.1007/s11136-024-03655-7. Epub 2024 May 9. Qual Life Res. 2024. PMID: 38724771 Free PMC article.
-
Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.Pharmacoeconomics. 2018 Feb;36(2):225-238. doi: 10.1007/s40273-017-0582-5. Pharmacoeconomics. 2018. PMID: 29270835 Free PMC article.
-
United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument.Med Decis Making. 2021 May;41(4):485-501. doi: 10.1177/0272989X211003569. Epub 2021 Apr 5. Med Decis Making. 2021. PMID: 33813946
-
Cancer-specific utility instrument for health economic evaluations: A synopsis of the EORTC QLU-C10D user manual and current validity evidence.Eur J Cancer. 2025 Feb 25;217:115235. doi: 10.1016/j.ejca.2025.115235. Epub 2025 Jan 13. Eur J Cancer. 2025. PMID: 39874909 Review.
-
Valuing quality of life for economic evaluations in cancer: navigating multiple methods.Expert Rev Pharmacoecon Outcomes Res. 2024 Dec;24(10):1101-1114. doi: 10.1080/14737167.2024.2393332. Epub 2024 Aug 20. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 39158365 Review.
Cited by
-
Assessing the performance of QLQ-C30 in predicting all-cause mortality in community cancer patients.BMC Cancer. 2025 Mar 7;25(1):421. doi: 10.1186/s12885-025-13624-z. BMC Cancer. 2025. PMID: 40055624 Free PMC article.
-
Mapping the EORTC QLQ-C30 and QLQ-LC13 to the SF-6D utility index in patients with lung cancer using machine learning and traditional regression methods.Health Qual Life Outcomes. 2025 Jul 1;23(1):66. doi: 10.1186/s12955-025-02394-8. Health Qual Life Outcomes. 2025. PMID: 40597342 Free PMC article.
-
Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and France.Pharmacoeconomics. 2025 Aug;43(8):937-953. doi: 10.1007/s40273-025-01501-3. Epub 2025 Apr 27. Pharmacoeconomics. 2025. PMID: 40287928 Free PMC article.
References
-
- Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer statistics, 2021. C Ca: A Cancer Journal for Clinicians, 71(1), 7–33. https://doi.org/10.3322/caac.21654 - DOI
-
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. C Ca: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660 - DOI
-
- McGuire, S., & WHO Press. (2016). World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, 2015. Adv Nutr, 7(2), 418–419. https://doi.org/10.3945/an.116.012211
-
- World Health Organization. (2020). World cancer report: Cancer research for cancer prevention. International Agency for Research on Cancer.
-
- Zheng, R. S., Zhang, S. W., Sun, K. X., Chen, R., Wang, S. M., Li, L., Zeng, H. M., Wei, W. W., & He, J. (2023). [Cancer statistics in China, 2016]. Zhonghua Zhong Liu Za Zhi, 45(3), 212–220. https://doi.org/10.3760/cma.j.cn112152-20220922-00647 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical